TRIPS-agreement

Criticism of, and content on the "Trade related aspects of intellectual property rights" 'agreement'
Lowered insulin price should be made permanent

the Lilly company has temporarily lowered the price of insulin to $35/month. As anybody who reads the paper knows, LOTS of Americans, both young and old, are dying because they cannot afford insulin's insane price.

Open letter asking 37 WTO Members to declare themselves eligible to import medicines manufactured under compulsory license in another country, under 31bis of TRIPS Agreement

Background In 2001, the World Trade Organization (WTO) began negotiations on the rules regarding patents and access to medicine. While several issues were clarified and resolved in the November 2001 “Doha Declaration on TRIPS and Public Health”, the negotiations took nearly two more years to adopt on August 30, 2003, a decision that was a limited “waiver of the export restriction” on medicines and diagnostic tests manufactured under a compulsory license. The final resolution was complicated. Among the controversial features was the definition of an “eligible importing member”, which allowed WTO members to declare themselves ineligible in some cases or in all cases. In 2017, this decision became a formal amendment to the TRIPS agreement. Today 37 members of the WTO are listed as ineligible to import medicines manufactured in another country under a compulsory license, including the governments of Australia, Canada, Iceland, Japan, New Zealand, Norway, Switzerland, the United Kingdom, United States, and the European Union, including the following member states: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden. On April 7, 2020, more than 30 groups and three dozen experts on health, law and trade sent an open letter to those 37 WTO members, asking that “countries to notify the WTO that they have changed their policy and now considers itself an eligible importing country, and in addition, to also use whatever legal means are available to revoke the opt-out as importing members, for goods manufactured under a compulsory license.”

Health Policy Watch: World Health Assembly Prepares For Show Of Unity On Global COVID-19 Response – But Potential Dispute Over Taiwan

Analysis 15/05/2020 • Elaine Ruth Fletcher The world seems set to make at least a symbolic display of unity in the battle against the COVID-19 pandemic at the upcoming World Health Assembly (WHA), which begins on Monday. The WHO’s 194 member states are expected to overwhelmingly approve a European Union-led Resolution that aims to step up the global COVID-19 response, and ensure equitable access to treatments and future vaccines. But the show is unlikely to go off as smoothly as some might hope, and not only because the 73rd Assembly is meeting for the first time ever in a virtual format.

ip-health mailing list Archives

Discussions of Intellectual Property and Health Care "To see the collection of prior postings to the list, visit the Ip-health Archives." This is one of the very best places to learn about the battle -access to medicines vs drug patents and the drug cartel. If you saw the film "Fire in the Blood" you saw how, in this era of global epidemics and corporate greed people must stand up for the rights of human beings to lifesaving drugs at affordable and not extortionate prices. This URL brings one straight to the list archives.

Access to Medicines: Panel Discussion at Georgetown University about the "Crime of the Century" the disastrous murder by drug prices, of millions shown and discussed in the award winning film, Fire in the Blood

Doctors Without Borders and the O'Neill Institute for National and Global Health Law at Georgetown University screen (the 2013 film) Fire in the Blood and a discussion of challenges and opportunities for access to medicines, featuring a panel of distinguished speakers representing a range of expertise in the field of access to medicines.

"Fire in the Blood": Millions Die in Africa After Big Pharma Blocks Imports of Generic AIDS Drugs (Democracy Now)

(From Democracy Now) The new documentary, "Fire in the Blood," examines how millions have died from AIDS because big pharmaceutical companies and the United States have refused to allow developing nations to import life-saving generic drugs. The problem continues today as the World Trade Organization continues to block the importation of generic drugs in many countries because of a trade deal known as the Trips Agreement. We're joined by the film's director, Dylan Mohan Gray, and Ugandan AIDS doctor Peter Mugyenyi, who was arrested for trying to import generic drugs, and is

The Hidden Holocaust -

25 years ago a scheme, to make drugs much more expensive, came into force - along with the WTO. with the creation of the WTO -and tellingly, this was also in the middle of an epidemic, like today.

Our right to regulate drug prices was signed away when we joined the WTO.

The TRIPS agreement is part of the WTO. It was meant to jack up the prices of drugs all around the world. GATS (another WTO agreement) gave countries another bargaining chip they could use, jobs. . A logical approach would be for us to dump both GATS and TRIPS at the same time. That would give the poor countries (And US) back our right to regulate prices and get affordable drugs, we could keep the potentially millions of jobs that could end up being traded away in GATS. We would also get back our right to have affordable healthcare, and prevent Medicare and Social Security from being privatized.

A Country in Denial, and not just about COVID-19

With our for-profit system being too expensive for the vast majority of Americans to afford without being bankrupted, due to very very high rates of uninsurance and underinsurance, a very great fear is that this COVID-19 epidemic will be the straw that breaks the camels back.

Global Trade and Public Health

"Global trade and international trade agreements have transformed the capacity of governments to monitor and to protect public health, to regulate occupational and environmental health conditions and food products, and to ensure affordable access to medications". (This basically means they have stolen the right to regulate, or are in the process of stealing it.)

PharmaMyths.net

The drug pricing policy web site of pricing expert Donald W. Light.

The WhistleBlower: Confessions of a Healthcare Hitman

By Peter Rost, MD This book is about drug prices, by a former Pfizer VP of marketing- An inside view of the drug industry, an industry that both saves the lives of people who have enough money to buy its increasingly expensive products, and also lobbies all around the world to keep its prices high. I'd also recommend watching the film "Fire in the Blood", which Peter Rost, the book's author, appears in, if you are interested in this subject.

High prices, poor access: What is Big Pharma fighting for in Brussels?

Big Pharma's lobby machine ground into top gear to defend its privileges, doing its best to remove or weaken regulatory measures. A close relationship with the Commission –which fails to take undue industry influence seriously– has played a key role, as has the lobbying firepower of Big Pharma. The top ten biggest spending companies, for example, have increased their lobby budget by €2 million since 2015, and Big Pharma's main lobby group EFPIA (European Federation of Pharmaceutical Industries and Associations) sits on eight of the Commission’s advisory groups. Big Pharma has also rolled out a PR offensive harnessing the powerful emotions around illness, designed to deflect criticism and narrow the scope for debate. Thanks to this lobbying arsenal, the industry has succeeded in influencing the review into pharma incentives and rewards (such as intellectual property rules), as well as a change to a type of patent extension called an SPC (supplementary protection certificate) which allows companies to extend the period of monopoly pricing. It has also affected a proposal for EU collaboration to assess how effective new medicines and health technologies are relative to existing ones, something which helps member states negotiate prices. Drug companies promote the use of ‘new’ drugs because they still have patent protection, and are therefore more expensive, over old ones that don't, even if the new product is not an improvement in medical terms.

Carrying a Good Joke Too Far: TRIPS and Treaties of Adhesion

"A small, unindustrialized country enters into an agreement with a significantly larger, more industrialized country. The agreement must be signed before the small country is permitted to join an exclusive, wealth- generating organization. The small country is facing an epidemic of epic proportions. Already, twenty-two million of its citizens have died as a result of a deadly virus and over thirty million of its citizens are infected. Almost three million die every year. Thirteen million children are orphaned; 15,000 new people acquire the virus every day. The average fifteen-year-old citizen has more than a fifty percent chance of dying of the virus and is more likely to die of the virus than all other causes combined. Finally, while the virus attacks indiscriminately, it impacts the country's economic driving force-its farmers, teachers, blue-collar workers, young adults, and parents -particularly hard. The disease is treatable, but at a cost well out of reach of the country's citizens. The country attempts to address this crisis by implementing two methods, parallel importation and compulsory licensing, which will drastically reduce prices and ensure the supply of drugs at affordable prices. Upon enactment, the larger industrialized country demands that the smaller country halt implementation because the methods violate its obligations under the agreement." (Sound familiar? It should.)

Canada's CCPA's (progressive NGO) submission on the USMCA (new NAFTA)

CCPA recommendations for a better North American trade model The all-party House of Commons trade committee is consulting Canadians on their priorities for bilateral and trilateral North American trade in light of the current renegotiation of NAFTA. In the CCPA’s submission to this process, Scott Sinclair, Stuart Trew, and Hadrian Mertins-Kirkwood argue for a different kind of trading relationship that is inclusive, transformative, and forward-looking—focused on today’s real challenges, including climate change, the changing nature of work, stagnant welfare gains, and unacceptable levels of inequality in all three North American countries. The CCPA submission largely repeats advice given to Global Affairs Canada during the department’s consultation on the NAFTA renegotiations, but is updated to take into account some of the proposals put forward by Canada and the U.S. during the first three rounds of talks.

Celebrating Fair Trade in Cancun

This PDF flyer from 2003 was published by IATP and distributed during the WTO Ministerial in Cancun, Mexico. In just a few words it does a good job of explaing some key concepts about the WTO. It also introduces for beginners some of the core concepts of the concept of Fair Trade, a non-exploitative alternative to market totalitarianism.

GATS: Increasing LDC participation through negotiated specific commitments (Art. IV:1) (United Nations)

This is about public procurement of both goods and services by governments at the federal, and increasingly, state or local level. One of the goals of the WTO Government Procuerment Agreement, as well as the GATS is allegedly to assist the poorest countries businesses by bending the rules for a limited time in their favor. Normally, in the case of jobs, the *lowest* bidder (who may not necessarily be a firm from the very poorest countries, it may instead be a highly automated firm or one from another low wage country, but not one of the poorest ones.) gets a legal entitlement to perform work. However under some limited circumstances, LDCs' firms (firms based in the very poorest countries) may be able to bid for contracts and win even if their price is a bit higher than the lowest bidders. (this is called a "set aside" in the US, where they had traditionally been used to funnel work to women and minority owned businesses. These kinds of set asides seem to be subsumed by the newer kind in trade agreements.) Note these dispensations like this LDC Services Waiver which gives the poorest countries opportunities to perform work in the wealthier countries, even if they charge a bit more are only available under limited circumstances and only to the (very poorest) "LDC" countries in order to assist in the policy goal of helping their firms enter the world's markets faster. Similar rules apply to allow the poorest countries access to life saving medicines in medical emergencies.